Healthcare Business

Are Allergan Shareholders Getting Enough in the AbbVie Acquisition?

Allergan PLC (NYSE: AGN) shares jumped on Tuesday after the company announced that it would be acquired by AbbVie Inc. (NYSE: ABBV) in a cash and stock transaction. The transaction ...
Read Full Story »

Why Akorn Is in Trouble With the FDA Again

Akorn Inc. (NASDAQ: AKRX) shares dipped on Tuesday after the firm announced that it received a warning letter from the U.S. Food and Drug Administration (FDA). Specifically, this letter is ...
Read Full Story »

Many Pregnant Women Get Too Much Folic Acid, New Study Finds

One piece of nutritional advice unfailingly drummed into the heads of women who are pregnant or trying to become pregnant is: Take plenty of folic acid. In a new study ...
Read Full Story »

How Minerva Neursciences Is Outsmarting Insomia

Minerva Neurosciences Inc. (NASDAQ: NERV) saw its shares jump on Monday after the firm announced results from a trial related to an insomnia treatment. Specifically, the results came from the ...
Read Full Story »

New Study Links Irregular Heartbeat and Dementia

A new large-scale study conducted by Korean researchers, the results of which were just published in the European Heart Journal, has established a significant link between the common cardiac arrhythmia ...
Read Full Story »

FDA Ignites Ocular Inflammation Treatment Dextenza in Most Recent Approval

Ocular Therapeutix, Inc. (NASDAQ: OCUL) shares jumped on Friday after the firm announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Dextenza ...
Read Full Story »

Study Shows How Pomegranates May Help Keep Us Younger

Swiss researchers have established that tannins found in pomegranates are converted in the digestive system into a compound that appears to slow down mitochondrial aging -- a natural process that ...
Read Full Story »

Why This FDA Approval for Pneumonia Treatment Is So Huge

This story has been updated for share price impact. Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares nearly doubled early on Wednesday after the firm announced that the U.S. Food and Drug ...
Read Full Story »

One Firm Sees Up to 45% Upside in Top Companies in Life Sciences Tools

Investing in the life sciences tool sector can be tricky, but according to the financial services firm Janney, the investing gain will be a result of finding the right secular ...
Read Full Story »

Two Very Speculative Biotechs With Promising Alzheimer’s Treatment Hopefuls

The biotechnology sector is generally considered the most volatile and riskiest sector within all of healthcare. Some companies have created massive wealth in this sector. And some companies have produced ...
Read Full Story »

Tuesday’s Top BioPharma Movers Deviating from the Market

Tuesday was a breakout day for a few biotech companies, and that was the case even before news broke that the U.S. and China would be meeting at the G20 ...
Read Full Story »

How PhaseBio Pharma Could Change the Game in Antiplatelet Therapy

Shares of PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) jumped on Tuesday after the firm announced preliminary results from its mid-stage trial for dual antiplatelet therapy of the blood thinner ticagrelor and ...
Read Full Story »

How Aclaris Is On Track to Treat Baldness

Baldness and hair thinning is something that many men and women fear as they age, and understandably so. But Aclaris Therapeutics, Inc. (NASDAQ: ACRS) may have found an answer to ...
Read Full Story »

Can This Pill Stave Off Alzheimer’s While Lowering Blood Pressure?

A blood pressure medication widely used in Europe and Japan might have potential to slow down the progress of Alzheimer’s disease, according to a new study appearing in Hypertension, a ...
Read Full Story »

How Much Is Pfizer Overpaying For Array Bio?

Array BioPharma Inc. (NASDAQ: ARRY) shares shot up on Monday after the firm announced that it would be acquired by Pfizer Inc. (NYSE: PFE) in an all cash transaction. The ...
Read Full Story »